Get the Stockscreener App
1.13
4.63%
0.05
After Hours:
1.13
Tscan Therapeutics Inc stock is traded at $1.13, with a volume of 1.01M.
It is up +4.63% in the last 24 hours and up +24.12% over the past month.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$1.08
Open:
$1.12
24h Volume:
1.01M
Relative Volume:
1.78
Market Cap:
$64.13M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-0.6313
EPS:
-1.79
Net Cash Flow:
$-64.50M
1W Performance:
+1.80%
1M Performance:
+24.12%
6M Performance:
-40.84%
1Y Performance:
-41.15%
1-Day Range:
$1.10
$1.185
1-Week Range:
$0.99
$1.185
52-Week Range:
$0.8824
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.13 | 61.29M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
FY2030 Earnings Estimate for TCRX Issued By HC Wainwright - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Price Target Raised to $5.00 - MarketBeat
Tscan Therapeutics earnings beat by $0.09, revenue topped estimates - Investing.com India
TCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TCRX: Pivotal trial for relapse-preventing T-cell therapy launches in Q2, targeting major market expansion - TradingView
TScan Therapeutics (NASDAQ:TCRX) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS - MarketBeat
TScan Therapeutics, Inc. (TCRX) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
TScan Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
The latest financial data from biotechnology company Tscan Therapeutics, Inc. shows that its current cash and cash equivalents are sufficient to support the company's daily operations and R&D investment through the second half of 2027. - Bitget
TScan Therapeutics 10-K: $10.3M Collaboration Revenue, $(129.8)M Net Loss - TradingView
TScan Therapeutics (NASDAQ: TCRX) advances TSC-101 and reshapes pipeline - Stock Titan
TScan Therapeutics (NASDAQ: TCRX) details 2025 loss, growth and cash runway - Stock Titan
Earnings Breakdown: TScan Therapeutics Q4 - Benzinga
TScan Therapeutics Q4 net loss widens - TradingView
BRIEF-TScan Therapeutics Q4 Net Income USD -22.977 Million - TradingView
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial - marketscreener.com
TScan readies pivotal T cell trial and new 2026 studies in hematologic cancers - Stock Titan
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 - Sahm
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
TScan Therapeutics to Present at TD Cowen 46th Annual Health Care Conference on March 4, 2026 - Quiver Quantitative
TScan Therapeutics (TCRX) Projected to Post Quarterly Earnings on Wednesday - Defense World
Is TScan Therapeutics Inc. stock a good dividend stockWeekly Stock Report & Risk Controlled Daily Plans - mfd.ru
TScan Therapeutics (NASDAQ:TCRX) Trading Up 4.6%Here's What Happened - MarketBeat
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Is TScan Therapeutics Inc. stock a value trap2025 Sector Review & Low Drawdown Trading Techniques - mfd.ru
What’s next for TScan Therapeutics Inc. stockQuarterly Market Review & Comprehensive Market Scan Insights - mfd.ru
What are TScan Therapeutics Inc.’s technical support levels2025 Momentum Check & Capital Protection Trade Alerts - mfd.ru
Net income of Tscan Therapeutics from 2020 to 2024 - Statista
Analysis Recap: Will TScan Therapeutics Inc outperform its industry peersJuly 2025 Breakouts & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Aug Highlights: How liquid is BlackRock ESG Capital Allocation Term Trust stock2025 Pullback Review & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Activity Recap: Will TScan Therapeutics Inc outperform its industry peersMarket Trend Summary & Proven Capital Preservation Methods - baoquankhu1.vn
Investor Mood: How does Waterstone Financial Inc perform in inflationary periodsQuarterly Market Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Financial Contrast: Urogen Pharma (NASDAQ:URGN) vs. TScan Therapeutics (NASDAQ:TCRX) - Defense World
Take Profit: Is TScan Therapeutics Inc. forming bullish engulfing patternsWeekly Stock Report & Safe Entry Momentum Tips - mfd.ru
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
TScan Therapeutics (NASDAQ:TCRX) Shares Up 1.8%What's Next? - MarketBeat
Jobs Data: How much upside does TScan Therapeutics Inc. haveTrade Entry Report & Real-Time Price Movement Reports - baoquankhu1.vn
Is TScan Therapeutics Inc. stock risky to hold nowMarket Sentiment Report & Daily Entry Point Alerts - bollywoodhelpline.com
Aug Volume: Will TScan Therapeutics Inc stock benefit from M AJuly 2025 Momentum & Verified Stock Trade Ideas - baoquankhu1.vn
Weekly Trades: Will TScan Therapeutics Inc stock benefit from M AMarket Trend Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
TScan Therapeutics Outlines Pivotal 2026 Outlook in Presentation - The Globe and Mail
TScan Therapeutics, Inc. Presents at J.P. Morgan Healthcare Conference - TradingView
Aug Momentum: How does TScan Therapeutics Inc score in quality rankingsEarnings Risk Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Is TScan Therapeutics Inc. stock a safe haven asset2025 AllTime Highs & Fast Gain Swing Alerts - ulpravda.ru
Is TScan Therapeutics Inc. stock dividend yield sustainableJuly 2025 Gainers & AI Driven Stock Movement Reports - ulpravda.ru
Breakout Move: How institutional buying supports TScan Therapeutics Inc stockJuly 2025 Action & Low Volatility Stock Recommendations - Bộ Nội Vụ
Institution Moves: Is TScan Therapeutics Inc. stock safe for conservative investorsOptions Play & Risk Adjusted Swing Trade Ideas - Улправда
Why TScan Therapeutics Inc. stock attracts global investorsRecession Risk & Reliable Breakout Stock Forecasts - Улправда
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tscan Therapeutics Inc Stock (TCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Dec 22 '25 |
Buy |
0.90 |
75,500 |
67,950 |
8,012,916 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 23 '25 |
Buy |
0.90 |
6,232 |
5,602 |
8,019,148 |
| Lynx1 Capital Management LP | 10% Owner |
May 19 '25 |
Buy |
1.20 |
1,388,794 |
1,666,553 |
6,746,141 |
| Lynx1 Capital Management LP | 10% Owner |
May 20 '25 |
Buy |
1.20 |
1,200,000 |
1,440,000 |
7,946,141 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):